IRIS
SANTORO, MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.509
AS - Asia 4.419
EU - Europa 3.492
SA - Sud America 722
AF - Africa 107
Continente sconosciuto - Info sul continente non disponibili 12
OC - Oceania 1
Totale 35.262
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.231
SG - Singapore 2.638
IT - Italia 652
CN - Cina 646
BR - Brasile 606
DE - Germania 557
HK - Hong Kong 465
SE - Svezia 355
IE - Irlanda 348
UA - Ucraina 308
RU - Federazione Russa 257
PL - Polonia 240
KR - Corea 236
CA - Canada 216
GB - Regno Unito 204
FR - Francia 194
VN - Vietnam 148
FI - Finlandia 125
NL - Olanda 64
ID - Indonesia 56
AT - Austria 55
MX - Messico 42
IN - India 40
ZA - Sudafrica 34
AR - Argentina 33
JP - Giappone 33
BD - Bangladesh 29
IQ - Iraq 29
ES - Italia 28
BE - Belgio 26
EC - Ecuador 20
CZ - Repubblica Ceca 19
TR - Turchia 16
CM - Camerun 15
PK - Pakistan 15
CL - Cile 14
VE - Venezuela 13
MA - Marocco 11
PH - Filippine 11
BO - Bolivia 10
CO - Colombia 10
EU - Europa 10
LT - Lituania 10
BG - Bulgaria 9
CH - Svizzera 9
RO - Romania 9
EG - Egitto 8
IR - Iran 8
KE - Kenya 8
AE - Emirati Arabi Uniti 6
DZ - Algeria 6
JO - Giordania 6
PY - Paraguay 6
UZ - Uzbekistan 6
JM - Giamaica 5
PT - Portogallo 5
UY - Uruguay 5
AO - Angola 4
AZ - Azerbaigian 4
IL - Israele 4
PA - Panama 4
PE - Perù 4
SA - Arabia Saudita 4
CI - Costa d'Avorio 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
GR - Grecia 3
HU - Ungheria 3
TN - Tunisia 3
TT - Trinidad e Tobago 3
TZ - Tanzania 3
AL - Albania 2
AM - Armenia 2
CR - Costa Rica 2
CY - Cipro 2
ET - Etiopia 2
GH - Ghana 2
HN - Honduras 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LB - Libano 2
LY - Libia 2
MN - Mongolia 2
NG - Nigeria 2
UG - Uganda 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BY - Bielorussia 1
DM - Dominica 1
EE - Estonia 1
GE - Georgia 1
GY - Guiana 1
MD - Moldavia 1
MK - Macedonia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
PS - Palestinian Territory 1
Totale 35.256
Salva come PNG Salva come JPEG
Città #
Woodbridge 6.937
Wilmington 6.847
Houston 5.422
Singapore 1.305
Fairfield 891
Ashburn 591
Chandler 551
Ann Arbor 508
Hong Kong 459
Seattle 394
Beijing 351
Dublin 316
Cambridge 305
Rome 265
Jacksonville 255
Medford 230
Kraków 213
Santa Clara 209
Dearborn 176
New York 174
Los Angeles 161
Dundas 130
The Dalles 116
Lawrence 108
Council Bluffs 87
Munich 86
Buffalo 82
Milan 60
San Diego 59
São Paulo 59
Nuremberg 58
Moscow 53
Zhengzhou 53
Dallas 51
Menlo Park 49
Ho Chi Minh City 46
Jakarta 45
London 44
Mülheim 41
Phoenix 34
Creede 30
Helsinki 30
Toronto 30
Denver 28
Hanoi 27
Lappeenranta 27
Boardman 26
Chicago 26
Falls Church 24
Redondo Beach 24
San Francisco 22
Vienna 22
Montreal 21
Tokyo 21
Dong Ket 20
Warsaw 20
Atlanta 19
Stockholm 19
Brussels 18
Johannesburg 18
Palermo 18
Colorado Springs 17
Orem 17
Amsterdam 16
Columbus 16
Belo Horizonte 15
Boston 15
Seoul 15
Brooklyn 14
Guangzhou 14
Mexico City 14
Poplar 14
Rio de Janeiro 14
Baghdad 13
Brno 13
Chennai 13
Nanjing 13
Norwalk 13
San Jose 13
Florence 12
Frankfurt am Main 12
Palo Alto 12
Porto Alegre 12
Redwood City 12
University Park 12
Cedarhurst 10
Kunming 10
Manchester 10
Mountain View 10
Querétaro 10
Brasília 9
Elk Grove Village 9
North Bergen 9
Pittsburgh 9
Verona 9
Durban 8
Guayaquil 8
Mumbai 8
Salt Lake City 8
Sofia 8
Totale 28.777
Salva come PNG Salva come JPEG
Nome #
Is there any potential for first-line etravirine use? Analysis from a large data set of antiretroviral therapy-naive HIV-infected patients undergoing resistance test 576
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 555
Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy 523
The Genotypic False Positive Rate Determined by Population V3-Sequencing can Predict the Burden of X4 Quasispecies Detected by Pyrosequencing 510
Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors 493
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 479
Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy 472
Comet assay and micronucleus test in circulating erythrocytes of Cyprinus carpio specimens exposed in situ to lake waters treated with disinfectants for potabilization 470
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients 468
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 466
Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice 459
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues 457
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 454
Comparative evaluation of subtyping tools for the surveillance of newly emerging HIV-1 strains 451
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors 450
Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure 448
Population dynamics of HIV-1 subtype B in a cohort of men-having-sex-with-men in Rome, Italy 445
Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study 440
Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen 437
The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: Evidences from literature 427
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment 424
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens 423
Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon 420
Dynamics of NRTI resistance mutations during therapy interruption 413
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 413
Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria 412
Non-B HIV type 1 subtypes among men who have sex with men in Rome, Italy 410
Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy 410
Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine 405
Molecular Epidemiology of HIV Type 1 CRF02_AG in Cameroon and African Patients Living in Italy 402
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. 402
HIV-1 R5+ /X4- tropic viruses can be inhibited in vitro as well as in vivo by maraviroc: a refined analysis of patients enrolled in the Phase IIb study A4001029 401
HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Cross-sectional Design 400
Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens 399
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations 396
Temporal change in the use of genotypic resistance testing over the years 1999--2003 394
An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project 394
Short communication: Population-based surveillance of HIV-1 drug resistance in cameroonian adults initiating antiretroviral therapy according to the world health organization guidelines 393
Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA 391
HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia 390
Circulation of HIV-1 CRF02_AG among MSM population in central Italy: a molecular epidemiology-based study 388
Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: An observational study using pooled European cohort data 388
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. 385
High Burden of HBV-Infection and Atypical HBV Strains among HIV-infected Cameroonians 380
Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels 377
The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing 373
Use of novel antiretroviral agents in rescue regimens: a case of early virological failure to raltegravir 370
Next-generation sequencing provides an added value in determining drug resistance and viral tropism in Cameroonian HIV-1 vertically infected children 370
Clinical relevance of genotypic resistance testing today 370
HIV-1 Genetic Variability and Clinical Implications 369
Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIRaben-1 subtype B and non-subtype B receiving a salvage regimen 369
Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score 368
Impact of pre-therapy viral load on virological response to modern first-line HAART 366
Drug Resistance Among Drug-naive and First-line Antiretroviral Treatment-failing Children in Cameroon 364
Characterization of drug resistance mutations in naive and ART-treated patients infected with HIV-1 in Yaounde, Cameroon 363
HIV-1 non-B subtypes in Italy: a growing trend 363
Genotypic tropism testing in HIV-1 proviral DNA can provide useful information at low-level viremia 362
Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen 358
Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score 354
Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice 350
Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000-14 347
Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients 343
Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy 339
The Lowest X4 Geno2Pheno-False Positive Rate Is Associated with Greater CD4-Depletion 338
Genetic divergence of HIV-1 B subtype in Italy over the years 2003–2016 and impact on CTL escape prevalence 327
The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate + emtricitabine-containing HAART both in vivo and in vitro 306
Recent transmission clustering of HIV-1 C and CRF17-BF strains characterized by NNRTI-related mutations among newly diagnosed men in central Italy 294
Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological success 288
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen 285
Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment 284
CEDRIC-HIV: la checklist per gli studi sulla resistenza ai farmaci anti-HIV 270
Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy 250
HIV MDR is still a relevant issue despite its dramatic drop over the years 217
New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T) 207
Is the rate of virological failure to cART continuing to decline in recent calendar years? 199
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors 198
Genetic diversity of HIV type 1 in Montenegro 188
Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir 184
HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: Evidence from routine clinical practice in Cameroon 178
Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy 171
Viral suppression in adults, adolescents and children receiving antiretroviral therapy in Cameroon: Adolescents at high risk of virological failure in the era of "test and treat" 154
Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients 152
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: A multicentre retrospective cohort study 133
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses 125
Frequency of atypical mutations in the spike glycoprotein in SARS-CoV-2 circulating from July 2020 to July 2022 in central Italy: a refined analysis by Next Generation Sequencing 118
Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration 114
Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b 106
Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings 103
Impact of analytical treatment interruption on burden and diversification of HIV peripheral reservoir: a pilot study 103
High performance of integrase genotyping on diverse HIV-1 clades circulating in Cameroon: toward a successful transition to dolutegravir-based regimens in low and middle-income countries 102
Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients 100
HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015-21 95
Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV 95
Impact of transmitted HIV-1 drug resistance on the efficacy of firstline antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor 92
Comparison of Different HIV-1 Resistance Interpretation Tools for Next-Generation Sequencing in Italy 91
Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings 85
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry 83
Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease 83
Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice 80
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy 79
Totale 32.265
Salva come PNG Salva come JPEG
Categoria #
all - tutte 99.278
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 99.278
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.977 0 0 0 0 0 515 599 407 84 121 152 99
2021/20221.345 56 76 83 49 59 91 54 37 346 129 57 308
2022/20231.684 170 137 87 178 159 348 113 168 137 37 102 48
2023/2024683 80 18 29 24 53 126 37 18 19 138 11 130
2024/20254.764 160 906 460 241 141 258 601 195 421 294 541 546
2025/20263.285 586 303 674 735 857 130 0 0 0 0 0 0
Totale 36.009